Cross-posted from HIV.gov as cross-posted from NIAID Newsroom
Tecovirimat Is Safe but Ineffective as Treatment for Clade II Mpox
NIH-Sponsored Trial Data Offer Further Evidence to Help Inform Mpox Treatment Decisions
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical trial sponsored by the National Institutes of Health (NIH). The trial enrollment was stopped in late 2024 when an interim analysis showed that tecovirimat monotherapy was ineffective in the study population. Detailed results were presented at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco. Read more of the newsroom release.
Read the CROI Abstracts on this study:
- 201 – Tecovirimat Is Safe but Not Efficacious in People With Clade II Mpox
- 159 – Host and Disease Factors Were Not Associated With Mpox Resolution in Participants Receiving Tpoxx
Find out how to access more from CROI2025 in What's Available to CROI 2025 Non-Attendees?
Read more about Mpox (CDC)